Literature DB >> 27617148

Li-Fraumeni Syndrome.

Hernán Correa1.   

Abstract

Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome caused by a germline mutation of the TP53 gene on chromosome 17p13.1. It has an autosomal dominant pattern of inheritance with high penetrance. These patients have a very high lifetime cumulative risk of developing multiple malignancies and have a strong family history of early-onset malignancies. The protein p53, encoded by TP53, has a complex set of genome-preserving functions initiated during episodes of cellular stress and DNA damage. In LFS, TP53 gene mutations cause the loss of function of p53, leading to downstream events permissive for development of various malignancies throughout life. The LFS component tumors include soft tissue sarcomas, osteosarcoma, premenopausal breast cancer, brain tumors, and adrenal cortical carcinomas. Multiple types of sarcomas have been reported in association with LFS; this review article will focus on the most frequently encountered pediatric sarcomas associated with TP53 mutations.

Entities:  

Keywords:  Li–Fraumeni syndrome; TP53; osteosarcoma; p53; rhabdomyosarcoma

Year:  2016        PMID: 27617148      PMCID: PMC4918696          DOI: 10.1055/s-0036-1579759

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  32 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  Segregation analysis of cancer in families of childhood soft-tissue-sarcoma patients.

Authors:  E D Lustbader; W R Williams; M L Bondy; S Strom; L C Strong
Journal:  Am J Hum Genet       Date:  1992-08       Impact factor: 11.025

3.  Germline TP53 variants and susceptibility to osteosarcoma.

Authors:  Lisa Mirabello; Meredith Yeager; Phuong L Mai; Julie M Gastier-Foster; Richard Gorlick; Chand Khanna; Ana Patiño-Garcia; Luis Sierrasesúmaga; Fernando Lecanda; Irene L Andrulis; Jay S Wunder; Nalan Gokgoz; Donald A Barkauskas; Xijun Zhang; Aurelie Vogt; Kristine Jones; Joseph F Boland; Stephen J Chanock; Sharon A Savage
Journal:  J Natl Cancer Inst       Date:  2015-04-20       Impact factor: 13.506

4.  TP53-Associated Pediatric Malignancies.

Authors:  Emilia M Pinto; Raul C Ribeiro; Bonald C Figueiredo; Gerard P Zambetti
Journal:  Genes Cancer       Date:  2011-04

5.  Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005.

Authors:  Simona Ognjanovic; Amy M Linabery; Bridget Charbonneau; Julie A Ross
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

6.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.

Authors:  Kelly D Gonzalez; Katie A Noltner; Carolyn H Buzin; Dongqing Gu; Cindy Y Wen-Fong; Vu Q Nguyen; Jennifer H Han; Katrina Lowstuter; Jeffrey Longmate; Steve S Sommer; Jeffrey N Weitzel
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH.

Authors:  S Selvarajah; M Yoshimoto; O Ludkovski; P C Park; J Bayani; P Thorner; G Maire; J A Squire; M Zielenska
Journal:  Cytogenet Genome Res       Date:  2008-10-14       Impact factor: 1.636

8.  Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program.

Authors:  Lisa Mirabello; Rebecca J Troisi; Sharon A Savage
Journal:  Cancer       Date:  2009-04-01       Impact factor: 6.860

9.  Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.

Authors:  Masafumi Seki; Riki Nishimura; Kenichi Yoshida; Teppei Shimamura; Yuichi Shiraishi; Yusuke Sato; Motohiro Kato; Kenichi Chiba; Hiroko Tanaka; Noriko Hoshino; Genta Nagae; Yusuke Shiozawa; Yusuke Okuno; Hajime Hosoi; Yukichi Tanaka; Hajime Okita; Mitsuru Miyachi; Ryota Souzaki; Tomoaki Taguchi; Katsuyoshi Koh; Ryoji Hanada; Keisuke Kato; Yuko Nomura; Masaharu Akiyama; Akira Oka; Takashi Igarashi; Satoru Miyano; Hiroyuki Aburatani; Yasuhide Hayashi; Seishi Ogawa; Junko Takita
Journal:  Nat Commun       Date:  2015-07-03       Impact factor: 14.919

10.  Excess risk of breast cancer in the mothers of children with soft tissue sarcomas.

Authors:  J M Birch; A L Hartley; H B Marsden; M Harris; R Swindell
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

View more
  23 in total

Review 1.  Genetic predisposition to hematologic malignancies: management and surveillance.

Authors:  Lucy A Godley; Akiko Shimamura
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

Review 2.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

3.  A novel germline mutation of TP53 with breast cancer diagnosed as Li-Fraumeni syndrome.

Authors:  Masaya Kai; Makoto Kubo; Sawako Shikada; Saori Hayashi; Takafumi Morisaki; Mai Yamada; Yuka Takao; Akiko Shimazaki; Yurina Harada; Kazuhisa Kaneshiro; Yusuke Mizuuchi; Koji Shindo; Masafumi Nakamura
Journal:  Surg Case Rep       Date:  2022-10-11

4.  Comparison of Colorectal and Endometrial Microsatellite Instability Tumor Analysis and Premm5 Risk Assessment for Predicting Pathogenic Germline Variants on Multigene Panel Testing.

Authors:  Alessandro Mannucci; C Sloane Furniss; Chinedu Ukaegbu; Miki Horiguchi; Tara Fehlmann; Hajime Uno; Matthew B Yurgelun; Sapna Syngal
Journal:  J Clin Oncol       Date:  2020-09-30       Impact factor: 44.544

5.  Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.

Authors:  Hagit Shani; Rinat Bernstein-Molho; Yael Laitman; Iris Netzer; Eitan Friedman
Journal:  Breast Cancer Res Treat       Date:  2021-01-15       Impact factor: 4.872

6.  p53 Is Not Required for High CIN to Induce Tumor Suppression.

Authors:  Laura C Funk; Jun Wan; Sean D Ryan; Charanjeet Kaur; Ruth Sullivan; Avtar Roopra; Beth A Weaver
Journal:  Mol Cancer Res       Date:  2020-09-18       Impact factor: 6.333

Review 7.  Biology of Bone Sarcomas and New Therapeutic Developments.

Authors:  Hannah K Brown; Kristina Schiavone; François Gouin; Marie-Françoise Heymann; Dominique Heymann
Journal:  Calcif Tissue Int       Date:  2017-12-13       Impact factor: 4.333

8.  Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice.

Authors:  Jane A Branca; Benjamin E Low; Ruth L Saxl; Jennifer K Sargent; Rosalinda A Doty; Michael V Wiles; Beth L Dumont; Muneer G Hasham
Journal:  Genes Cancer       Date:  2020

Review 9.  Hereditary pancreatic cancer: related syndromes and clinical perspective.

Authors:  Sergio Carrera; Aintzane Sancho; Eider Azkona; Josune Azkuna; Guillermo Lopez-Vivanco
Journal:  Hered Cancer Clin Pract       Date:  2017-06-28       Impact factor: 2.857

Review 10.  Hematologic malignancies and Li-Fraumeni syndrome.

Authors:  Mahesh Swaminathan; Sarah A Bannon; Mark Routbort; Kiran Naqvi; Tapan M Kadia; Koichi Takahashi; Yesid Alvarado; Farhad Ravandi-Kashani; Keyur P Patel; Richard Champlin; Hagop Kantarjian; Louise Strong; Courtney D DiNardo
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.